Biological drugs are currently used for the treatment of vasculitis, such as anti-TNF-alpha agents (infliximab, etanercept, adalimumab, golimumab, and certolizumab), anti-interleukin (IL)-6-receptor antibody (tocilizumab), and anti-CD20 antibody (rituximab) [6,8,9]. The gene discussed is TNF; the disease is vasculitis.